The Evolving Landscape of Antibody–Drug Conjugates for Urothelial Carcinoma
Melissa L. Abel(National Institutes of Health), Alexandra Drakaki(Columbia University Irving Medical Center), Aaron Burkenroad(University of California, Los Angeles), Eric Lu(Ronald Reagan UCLA Medical Center), A. Sun(University of Toronto), Dimitrios Stefanoudakis(APLA Health)
Cited by 10
Related Papers
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2021|411
Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer
|Current Issues in Molecular Biology|2024|78